ICLUSIG (ponatinib) delivered clinically meaningful response in Ph+ ALL1,2

IN THE PACE TRIAL

PACE TRIAL DESIGN

The PACE trial showed ICLUSIG monotherapy helped difficult-to-treat patients 
with Ph+ ALL achieve a response1,2 

The PACE trial for ICLUSIG was a single-arm, open-label, international, multicenter, phase 2 trial in adult patients with CML or Ph+ ALL, resistant or intolerant to 2 TKIs, or who had the T315I mutation, regardless of prior TKI use. The primary endpoint for Ph+ ALL was MaHR by 6 months.1,2

In PACE, the starting dose of ICLUSIG (ponatinib) was 45 mg administered orally once daily, given as a single agent. Median duration of follow-up for the Ph+ ALL cohort was 6 months.2 Patients with uncontrolled hypertriglyceridemia and patients with clinically significant or active cardiovascular disease, including any history of clinically significant atrial/ventricular arrhythmias or history of myocardial infarction, unstable angina, or congestive heart failure within the 3 months prior to the first dose of ICLUSIG (ponatinib), were excluded.1,2
aResistance in Ph+ ALL was defined as failure to achieve either a MaHR (by 1 month in Ph+ ALL), loss of MaHR (at any time), or development of a kinase domain mutation in the absence of a complete MaHR while on prior TKI therapy. Intolerance was defined as the discontinuation of prior TKI therapy due to toxicities despite optimal management in the absence of MaHR for patients with Ph+ ALL.1

Patient characteristics

In the PACE clinical trial, the vast majority of study patients (84%) were TKI-resistant and 69% of patients had the T315I mutation.3 
Patient characteristics
Patient characteristics at entry for Ph+ ALL showing a median age of 62 years, previous TKI use, mutation status, and treatment history.

69%.

69% of patients with Ph+ ALL were T315I+ in the PACE trial3

Patients taking ICLUSIG reached important markers of response1

41%.

41% of patients achieved MaHR by 6 months1,a,b (n=32)

The primary efficacy endpoint for 
Ph+ ALL was MaHR by 6 months1

  • Median time to MaHR 0.7 months (range: 0.4-6.0 months)1
  • Median duration of MaHR 3.5 months (range: 1.9-13.7 months)1
  • Median duration of follow-up for the Ph+ ALL cohort was 6 months.4

aThe primary endpoint for Ph+ ALL of MaHR by 6 months combined complete hematologic responses (CHR) and no evidence of leukemia.1

bCHR: WBC ≤ institutional ULN; ANC ≥1000/mm3; platelets ≥100,000/mm3; no blasts or promyelocytes in peripheral blood; bone marrow blasts ≤5; <5% myelocytes plus metamyelocytes in peripheral blood; basophils <5% in peripheral blood; and no extramedullary involvement (including no hepatomegaly or splenomegaly).1

Cytogenetic responses at any time4

Response rates for Ph+ ALL: ICLUSIG delivered clinically meaningful responses4
ICLUSIG (ponatinib) delivered a response rate of 38% for CCyR and 47% for MCyR in Ph+ ALL patients.

View ICLUSIG safety profile in the PACE trial

View ICLUSIG dosing in Ph+ ALL

ANC=absolute neutrophil count; AP-CML=accelerated-phase chronic myeloid leukemia; CCyR=complete cytogenetic response; CHR=complete hematologic response; MaHR=major hematological response; MCyR=major cytogenetic response; Ph+ ALL=Philadelphia chromosome-positive acute lymphoblastic leukemia; TKI=tyrosine kinase inhibitor; ULN=upper limit of normal for the lab; WBC=white blood cell.

Ph+ ALL Patient Profiles

""

Ph+ ALL Dosing Guide

""

Ph+ ALL resources and support

""